Research never stops

CHDI/Various

CHDI Inc., a not-for-profit organisation pursuing a biotech approach to finding therapies for Huntington’s disease, has chosen Evotec as a strategic partner for helping them advance its drug discovery programmes.

Since March 2006, Evotec and CHDI have a number of agreements covering integrated biology and chemistry supported by compound and library management, target validation, stem cell research, high-content screening, computational chemistry, in vitro pharmacokinetics and protein production. These contracts cover most of Evotec's integrated discovery offering. In September 2015, the collaboration was extended through August 2018. With access to these resources, CHDI has all the tools in place to rapidly discover novel drugs against Huntington’s disease targets and further optimise them to the point of clinical development.

About Huntington’s disease
Huntington’s disease is a familial disease caused by a mutation in the huntingtin gene. Each child of a parent with the mutation in the huntingtin gene has a 50-50 chance of inheriting the mutation. As a result of carrying the mutation, an individual's brain cells fail and die leading to cognitive and physical impairments that, over the course of the disease, significantly impair the individual's quality of life and ultimately cause death. Symptoms of Huntington’s disease, which generally develop in midlife and become progressively more debilitating as time passes, can also develop in infancy or old age. Once overt symptoms start, patients live for about 15 to 20 years. One person in 10,000 is believed to carry a mutation in the huntingtin gene. There is currently no way to delay the onset of symptoms or slow the progression of Huntington’s disease.